- Human pathology

Home > A. Molecular pathology > kinase fusions

kinase fusions

Wednesday 29 April 2020

- genetic alterations activating MAPK signaling

- 0.6% of metastati breast cancer harbor fusions (doi : 10.1016/j.annonc.2020.04.008 )

  • Kinase fusions in breast cancers are extremely rare, and appear to be enriched in hormone-resistant, metastatic carcinomas and mutually exclusive with ESR1 mutations.
  • Molecular testing at progression after endocrine therapy should include fusion testing, particularly in the absence of ESR1 hotspot alterations, in an effort to identify additional therapeutic options which may provide substantial clinical benefit.
  • Fused genes